

BIOGEN IDEC INC.
Form 3
June 10, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Sandrock Alfred
(Last) (First) (Middle)

BIOGEN IDEC INC.,Â 133
BOSTON POST RD.

(Street)

WESTON,Â MAÂ 02493

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
06/03/2013

3. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [BIIB]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer Other
(give title below) (specify below)
Grp SVP, Chief Medical Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

Common Stock

2. Amount of Securities Beneficially Owned (Instr. 4)

14,500

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

D Â

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)
Title

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Edgar Filing: BIOGEN IDEC INC. - Form 3

| | Date Exercisable | Expiration Date | | Amount or Number of Shares | | or Indirect (I) (Instr. 5) | |
|-----------------------------|------------------|-----------------|--------------|----------------------------|----------|----------------------------|---|
| Restricted Stock Unit | Â (1) | 02/23/2014 | Common Stock | 1,988 | \$ 0 | D | Â |
| Restricted Stock Unit | Â (1) | 02/09/2015 | Common Stock | 3,648 | \$ 0 | D | Â |
| Restricted Stock Unit | Â (1) | 02/08/2016 | Common Stock | 3,832 | \$ 0 | D | Â |
| Restricted Stock Unit | Â (1) | 02/12/2017 | Common Stock | 3,173 | \$ 0 | D | Â |
| Stock Option (Right to Buy) | Â (2) | 02/12/2013 | Common Stock | 15,030 | \$ 60.56 | D | Â |
| Stock Option (Right to Buy) | Â (3) | 02/23/2013 | Common Stock | 9,820 | \$ 49.65 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|----------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Sandrock Alfred BIOGEN IDEC INC. 133 BOSTON POST RD. WESTON, MA 02493 | Â | Â | Â Grp SVP, Chief Medical Officer | Â |

Signatures

Matthew S. Gilman, Attorney in Fact for Alfred W. Sandrock, Jr.

06/10/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date.

- (1) The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
- (2) The stock options became exercisable in four (4) equal annual installments commencing one year after the grant date of 02/12/08.
- (3) The stock options became exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.